Haris Ali, MD, discusses research supporting the use of ruxolitinib for the treatment of myelofibrosis.
Haris Ali, MD, a hematologist/oncologist and associate clinical professor, Department of Hematology & Hematopoietic Cell Transplantation at the City of Hope Comprehensive Cancer Center, discusses research supporting the use of ruxolitinib (Jakafi) for the treatment of myelofibrosis.
According to Ali, COMFORT-1 (NCT00952289) and COMFORT-2 (NCT00934544), showed that ruxolitinib showed good responses when compared to best available treatment or other supportive treatments. It was also shown beneficial for the treatment of polycythemia vera.
Ruxolitinib was recently approved for the treatment of graft versus host disease (GvHD) and has shown promise in chronic GvHD. According to Ali, this is due to the unique mechanism of improving inflammation, which is the main driver in patients with myelofibrosis, other myeloproliferative neoplasms, and GvHD.